Results
neuropathic, neuropathic pain, pain
Table 
The descriptive indexes result of homogeneity gender, and medications of the participants according to their groups* Chi-squared test; ** Fisher’s exact testAs can be seen in Table 
The descriptive indexes and background information homogeneity of the patients suffering from neuropathic pain in pre-intervention and post-intervention stages (two, four, and eight weeks after the initiation of the intervention)NOTE: Fre = Frequency; Per = Percentage; * Chi-squared test; ** Fisher’s exact testAs shown in Table 
The Descriptive indices and independent t-test results for neuropathic pain and neuropathic pain intensity of the participants based on the stages evaluation and their groups* P < 0.05; ** P < 0.01Note: M = Mean; SD = Standard deviationAs shown in Table Table 
The ANCOVA results for comparing the neuropathic pain between the study groups in the second, third, and fourth assessment stages* Effect Size: A numerical value that determines the difference between data and a statistical hypothesisIt is demonstrated in Table 
The results of multivariate test for severity of neuropathic painAs shown in Table 
The Results of multivariate test effects for neuropathic pain severity (based on the pain visual analog scale scores) for each research groupAccording to Table According to the results of the Bonferroni posthoc test, in the experimental group (clonidine + gabapentin), there are significant differences in terms of neuropathic pain severity between the first assessment and the other three assessment stages (P < 0.001). Also, the second assessment stages significantly differ from the third and fourth stages in neuropathic pain severity (P < 0.005). However, stages three and four are not significantly different (P > 0.05). Also, based on the results of the Bonferroni test in the control group (gabapentin), a significant difference was shown between the first assessment and the rest of the assessment stages (P < 0.05) and between the second assessment and the third and fourth assessment (P < 0.05). Despite these findings, no significant difference was discovered between stages three and four (P > 0.05). Figure 
The interactive effects of the assessment stages and the study groups in terms of neuropathic pain severityIn addition, based on the results of multivariate effects between groups, there is a significant difference between the research groups regarding the severity of neuropathic pain (F = 22.42, P < 0.001). In addition, eta squared demonstrates that compared to gabapentin, prescribing clonidine combined with gabapentin can explain 0.44 of the between-group variances of the severity of neuropathic pain.